Possible Bearish Signals With Rocket Pharmaceuticals Insiders Disposing Stock
Possible Bearish Signals With Rocket Pharmaceuticals Insiders Disposing Stock
The fact that multiple Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) insiders offloaded a considerable amount of shares over the past year could have raised some eyebrows amongst investors. Knowing whether insiders are buying is usually more helpful when evaluating insider transactions, as insider selling can have various explanations. However, when multiple insiders sell stock over a specific duration, shareholders should take notice as that could possibly be a red flag.
Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT)多位內部人士在過去一年大量賣出股票的事實可能引起了投資者的關注。在評估內部交易時,了解內部人士是否在買入股票通常更有幫助,因爲內部人士賣出股票可能有多種解釋。但是,當多個內部人士在特定時間段內出售股票時,股東應該注意到,因爲這可能是一個紅旗信號。
While we would never suggest that investors should base their decisions solely on what the directors of a company have been doing, we do think it is perfectly logical to keep tabs on what insiders are doing.
雖然我們絕不建議投資者僅基於公司董事所做的事情來作出決策,但我們認爲密切關注內部人士所做的事情是完全合理的。
The Last 12 Months Of Insider Transactions At Rocket Pharmaceuticals
Rocket Pharmaceuticals上市以來內部交易情況總結
The CEO & Director, Gaurav Shah, made the biggest insider sale in the last 12 months. That single transaction was for US$605k worth of shares at a price of US$29.84 each. While we don't usually like to see insider selling, it's more concerning if the sales take place at a lower price. The good news is that this large sale was at well above current price of US$19.04. So it is hard to draw any strong conclusion from it.
董事兼CEO Gaurav Shah在過去12個月中進行了最大額的內部交易。那筆單獨的交易是以每股29.84美元的價格購買了60.5萬美元的股票。通常情況下,我們不喜歡看到內部人士賣出股票,但如果銷售價格較低,則更加令人擔憂。好消息是,這次大規模售賣的價格高於現價19.04美元。因此,很難從中得出任何強烈的結論。
Rocket Pharmaceuticals insiders didn't buy any shares over the last year. You can see a visual depiction of insider transactions (by companies and individuals) over the last 12 months, below. By clicking on the graph below, you can see the precise details of each insider transaction!
Rocket Pharmaceuticals內部人士在過去一年內沒有購買任何股份。你可以看到下面過去12個月內內部交易(包括公司和個人)的可視化描述。通過點擊下面的圖表,您可以查看每個內部交易的詳細信息!
If you like to buy stocks that insiders are buying, rather than selling, then you might just love this free list of companies. (Hint: Most of them are flying under the radar).
如果你喜歡購買內部人員正在購買而不是銷售的股票,那麼你可能會喜歡這份免費的公司列表。(提示:它們中的大部分都被忽視了。)
Rocket Pharmaceuticals Insiders Are Selling The Stock
Rocket Pharmaceuticals內部人士正在拋售該股票
The last three months saw significant insider selling at Rocket Pharmaceuticals. Specifically, insiders ditched US$453k worth of shares in that time, and we didn't record any purchases whatsoever. This may suggest that some insiders think that the shares are not cheap.
過去三個月,Rocket Pharmaceuticals的內部人士大量拋售了股票。具體來說,內部人士在這段時間內拋售了45.3萬美元的股票,而我們沒有記錄任何購買記錄。這可能意味着一些內部人士認爲股票不便宜。
Does Rocket Pharmaceuticals Boast High Insider Ownership?
Rocket Pharmaceuticals內部人士持股高嗎?
Another way to test the alignment between the leaders of a company and other shareholders is to look at how many shares they own. We usually like to see fairly high levels of insider ownership. Rocket Pharmaceuticals insiders own about US$44m worth of shares. That equates to 2.5% of the company. We've certainly seen higher levels of insider ownership elsewhere, but these holdings are enough to suggest alignment between insiders and the other shareholders.
測試公司領導人與其他股東之間的關係的另一種方法是查看他們擁有的股數。我們通常希望看到相當高水平的內部人士持股比例。Rocket Pharmaceuticals的內部人員擁有約4400萬美元的股份,相當於該公司的2.5%。我們當然看到其他地方持股比例更高,但這些持股足以表明內部人士與其他股東之間的關係良好。
So What Does This Data Suggest About Rocket Pharmaceuticals Insiders?
那麼,這些數據對Rocket Pharmaceuticals的內部人士意味着什麼呢?
Insiders sold stock recently, but they haven't been buying. And there weren't any purchases to give us comfort, over the last year. Insider ownership isn't particularly high, so this analysis makes us cautious about the company. So we'd only buy after careful consideration. So these insider transactions can help us build a thesis about the stock, but it's also worthwhile knowing the risks facing this company. Case in point: We've spotted 4 warning signs for Rocket Pharmaceuticals you should be aware of, and 1 of these is significant.
內部人士最近拋售了股票,但他們沒有購買。過去一年中也沒有任何購買記錄,這讓我們對該公司持謹慎態度。內部人士持股比例並不特別高,因此這份分析讓我們對該公司保持謹慎。因此,在仔細考慮後才會購買。因此,這些內部交易可以幫助我們建立有關該股票的論點,但是知道這家公司面臨的風險也很值得。例如:我們發現了Rocket Pharmaceuticals 4個警告信號,您應該注意其中1個是重要警告信號。
But note: Rocket Pharmaceuticals may not be the best stock to buy. So take a peek at this free list of interesting companies with high ROE and low debt.
請注意:Rocket Pharmaceuticals可能不是最好的股票購買選擇。因此,請查看具有高roe和低負債的有趣公司的免費列表。
For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.
對於本文而言,內部人是指向相關監管機構報告其交易的個人。我們目前僅考慮公開市場交易和直接利益的私人處置,但不包括衍生交易或間接利益。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
對本文有任何反饋?對內容有任何疑慮?請直接與我們聯繫。或者,發送電子郵件至editorial-team@simplywallst.com。
這篇文章是Simply Wall St的一般性文章。我們根據歷史數據和分析師預測提供評論,只使用公正的方法論,我們的文章並不意味着提供任何金融建議。文章不構成買賣任何股票的建議,也不考慮您的目標或您的財務狀況。我們的目標是帶給您基本數據驅動的長期關注分析。請注意,我們的分析可能不考慮最新的價格敏感公司公告或定性材料。Simply Wall St沒有任何股票頭寸。
譯文內容由第三人軟體翻譯。